Insiders Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/04/2026 BST			5-day change	1st Jan Change
87.71 ^USD	+1.82%		+3.13%	+12.72%

04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI

Insiders

02-26	Kymera Therapeutics Appoints Neil Graham, MBBS, MD, MPH, as Chief Development Officer	CI
02-25	Kymera Therapeutics Insider Sold Shares Worth $2,707,813, According to a Recent SEC Filing	MT
12-31	Kymera Therapeutics Insider Sold Shares Worth $2,341,939, According to a Recent SEC Filing	MT
12-18	Kymera Therapeutics Insider Sold Shares Worth $2,264,480, According to a Recent SEC Filing	MT
12-15	Kymera Therapeutics Insider Sold Shares Worth $21,699,044, According to a Recent SEC Filing	MT
12-09	Kymera Therapeutics Insider Sold Shares Worth $8,917,000, According to a Recent SEC Filing	MT
12-09	Kymera Therapeutics Insider Sold Shares Worth $4,371,833, According to a Recent SEC Filing	MT
29/10/25	Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing	MT
15/10/25	Kymera Therapeutics Insider Sold Shares Worth $3,659,254, According to a Recent SEC Filing	MT
14/10/25	Kymera Therapeutics Insider Sold Shares Worth $295,949, According to a Recent SEC Filing	MT
16/09/25	Kymera Therapeutics Insider Sold Shares Worth $1,470,000, According to a Recent SEC Filing	MT
03/09/25	Kymera Therapeutics, Inc. Appoints Brian Adams as Chief Legal Officer and Corporate Secretary	CI
04/06/25	Kymera Therapeutics Insider Sold Shares Worth $1,470,000, According to a Recent SEC Filing	MT
09/04/25	Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer	CI
27/02/25	Kymera Therapeutics, Inc. Announces Leigh Morgan, A Member of the Board of Directors, the Compensation and Talent Committee of the Board, and A Member and Chair of the Nominating and Corporate Governance Committee of the Board, Not Intend to Stand for Reelection	CI
20/06/24	Kymera Therapeutics, Inc. Announces Board and Committee Changes	CI
01/04/24	Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board	CI
14/03/24	Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing	MT
24/01/24	Kymera Therapeutics Insider Sold Shares Worth $300,470, According to a Recent SEC Filing	MT
22/05/23	Kymera Therapeutics Appoints Jeremy Chadwick COO	MT
22/05/23	Kymera Appoints Jeremy Chadwick as Chief Operating Officer	CI
27/02/23	Kymera Therapeutics, Inc. Announces Departure of Elaine Caughey as Chief Business Officer	CI
17/01/23	Insider Sell: Kymera Therapeutics	MT
04/01/23	Kymera Therapeutics, Inc. Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary	CI
16/12/22	Insider Sell: Kymera Therapeutics	MT